Cancer Lett
2023 Feb 1:554:216011.
doi: 10.1016/j.canlet.2022.216011. Epub 2022 Nov 26.
Saikosaponin A enhances Docetaxel efficacy by selectively inducing death of dormant prostate cancer cells through excessive autophagy
Jiling Feng 1, Zhichao Xi 2, Xue Jiang 3, Yang Li 4, Wan Najbah Nik Nabil 5, Mengfan Liu 6, Zejia Song 7, Xiaoqiong Chen 8, Hua Zhou 9, Qihan Dong 10, Hongxi Xu 11
Affiliations expand
PMID: 36442771
DOI: 10.1016/j.canlet.2022.216011
Free article
Abstract
Quiescent cancer cells (QCCs), also known as dormant cancer cells, resist and survive chemo- and radiotherapy, resulting in treatment failure and later cancer recurrence when QCCs resume cell cycle progression. However, drugs selectively targeting QCCs are lacking. Saikosaponin A (SSA) derived from Bupleurum DC., is highly potent in eradicating multidrug-resistant prostate QCCs compared with proliferative prostate cancer cells. By further exacerbating the already increased autophagy through inactivation of Akt-mTOR signaling, SSA triggered cell death in QCCs. Contrarily, inhibition of autophagy or activation of Akt signaling pathway prevented SSA-induced cell death. The multicycle of Docetaxel treatments increased the proportion of QCCs, whereas administering SSA at intervals of Docetaxel treatments aggravated cell death in vitro and led to tumor growth arrest and cell death in vivo. In conclusion, SSA is posed as a novel QCCs-eradicating agent by aggravating autophagy in QCCs. In combination with the current therapy, SSA has potential to improve treatment effectiveness and to prevent cancer recurrence.
Keywords: Akt; Induce autophagy; Prostate cancer; Quiescent cancer cells; SSA.
参考连接：
https://pubpeer.com/publications/B6E8E4FE778382F8D9758B450823B2
本文为【丰倍SCI】公众号原创文章
未经授权禁止转载！
转载请勿更改原文内容及格式！
如有转载需求或合作事宜
可添加下方客服微信
或后台私信小编
三重保障：Al查重＋机械物理查重＋人工查重
官网：www.fengbei-ai.com
客服微信：sindy01010101
